Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

C

Brown TT, Moser C, Currier JS, et al. "Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir." J. Infect. Dis.. 2015;212(8):1241-9.
Bhagwat P, Ofotokun I, McComsey GA, et al. "Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes." Antivir. Ther. (Lond.). 2017;22(7):577-586.
Havers FP, Detrick B, Cardoso SW, et al. "Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings." PLoS ONE. 2014;9(4):e95164.
Shikuma CM, Ribaudo HJ, Zheng Y, et al. "Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals." AIDS Res. Hum. Retroviruses. 2011;27(5):461-8.
Hughes MD, Williams PL. "Challenges in using observational studies to evaluate adverse effects of treatment." N. Engl. J. Med.. 2007;356(17):1705-7.
Taiwo B, Hunt PW, Gandhi RT, et al. "CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2013;63(1):101-4.
Judge CJ, Kostadinova L, Sherman KE, et al. "CD56NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections." J. Leukoc. Biol.. 2017;102(1):171-184.
Vahey MT, Wang Z, Su Z, et al. "CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway." AIDS Res. Hum. Retroviruses. 2008;24(8):1047-66.
Tassiopoulos K, Landay A, Collier AC, et al. "CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies." J. Infect. Dis.. 2012;205(11):1730-8.
Judge CJ, Sandberg JK, Funderburg NT, et al. "CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy." J. Acquir. Immune Defic. Syndr.. 2016.
Henrich TJ, Hanhauser E, Harrison LJ, et al. "CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2016;213(5):766-70.
Shaffer D, Hughes MD, Sawe F, et al. "Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)." J. Acquir. Immune Defic. Syndr.. 2014;66(2):155-63.

B

Dumond JB, Rigdon J, Mollan K, et al. "Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results." J. Acquir. Immune Defic. Syndr.. 2015;70(5):510-4.
Treasure GC, Aga E, Bosch RJ, et al. "Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials." J. Acquir. Immune Defic. Syndr.. 2016;72(3):310-3.
Kelesidis T, Moser CB, Johnston E, et al. "Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s." J. Acquir. Immune Defic. Syndr.. 2018;78(3):362-366.
Macatangay BJ, Yang M, Sun X, et al. "Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217." J. Acquir. Immune Defic. Syndr.. 2017;75(1):137-141.
Haas DW, Bradford Y, Verma A, et al. "Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events." Pharmacogenet. Genomics. 2018;28(7):179-187.
Gupta SK, Yeh E, Kitch DW, et al. "Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s." J. Antimicrob. Chemother.. 2017;72(7):2042-2048.
Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
Palermo B, Bosch RJ, Bennett K, Jacobson JM. "Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy." HIV Clin Trials. 2011;12(4):222-7.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.
McComsey GA, Moser C, Currier J, et al. "Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s." Clin. Infect. Dis.. 2016;62(7):853-62.
Kiser JJ, Lu D, Rosenkranz SL, et al. "Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s." Drugs R D. 2017;17(4):557-567.
Sax PE, Komarow L, Finkelman MA, et al. "Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia." Clin. Infect. Dis.. 2011;53(2):197-202.
Halvas EK, Aldrovandi GM, Balfe P, et al. "Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency." J. Clin. Microbiol.. 2006;44(7):2612-4.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
Sattler FR, Chelliah D, Wu X, et al. "Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD Cells." Pathog Immun. 2018;3(1):46-62.
Lederman MM, Penn-Nicholson A, Cho M, Mosier D. "Biology of CCR5 and its role in HIV infection and treatment." JAMA. 2006;296(7):815-26.
De Boni RB, Zheng L, Rosenkranz SL, et al. "Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals." Drug Alcohol Depend. 2016;159:174-80.

Pages